Naloxone Hydrochloride Injection, Usp, Auto-injector

Naloxone is a potent opioid antagonist used for the emergency treatment of known or suspected opioid overdose. It works by rapidly reversing respiratory depression and central nervous system sedation caused by opioid agonists.

The dosage of Naloxone depends entirely on the clinical situation and the route of administration. Because the primary goal is the restoration of adequate spontaneous breathing, doses may need to be repeated.

• Intranasal Administration: The standard dose for most over-the-counter and prescription nasal sprays (like Narcan) is 4 mg delivered as a single spray into one nostril. If the person does not respond or begins to stop breathing again, additional 4 mg doses may be administered every 2 to 3 minutes using a new device in alternating nostrils.
• Intramuscular/Subcutaneous Injection: The initial dose is typically 0.4 mg to 2 mg. If the desired degree of counteraction is not obtained, it may be repeated at 2 to 3-minute intervals. If no response is observed after 10 mg has been administered, the diagnosis of opioid-induced toxicity should be questioned.
• Intravenous Injection: In a clinical setting, healthcare providers may start with 0.4 mg to 2 mg IV, which can be titrated upward. For postoperative reversal, smaller doses (0.1 mg to 0.2 mg) are often used to avoid sudden, severe pain and withdrawal.

Naloxone is safe and approved for use in pediatric patients, including neonates, for the reversal of opioid effects.

• Infants and Children: The typical dose for emergency reversal is 0.01 mg/kg. If this dose does not result in the desired clinical response, a subsequent dose of 0.1 mg/kg may be administered.
• Neonates: For opioid-induced depression at birth, the standard dose is 0.01 mg/kg administered into the umbilical vein, or via IM or SC routes.
• Adolescents: Dosing for teenagers generally follows adult protocols, particularly for community-based nasal spray administration (4 mg per dose).

Renal Impairment

Specific dosage adjustments for patients with renal (kidney) impairment are not typically required for emergency administration. However, because Naloxone metabolites are excreted renally, patients with end-stage renal disease should be monitored closely for any prolonged effects or unusual reactions during the recovery phase.

Hepatic Impairment

Naloxone undergoes significant hepatic (liver) metabolism. In patients with severe hepatic impairment or cirrhosis, the plasma levels of Naloxone may be higher than average. While this does not change the initial emergency dose, it may influence the duration of the drug’s effect and the severity of precipitated withdrawal symptoms.

Elderly Patients

Clinical studies of Naloxone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

Naloxone administration is an emergency procedure. If you are using the nasal spray:

1. 1Identify the Overdose: Look for blue lips/fingernails, pinpoint pupils, and slow or no breathing.
2. 2Call 911: Always seek professional emergency medical help immediately.
3. 3Prepare the Device: Remove the nasal spray from the packaging. Do not 'prime' or test the device, as it contains only one dose.
4. 4Administer: Tilt the person's head back, insert the tip of the nozzle into a nostril until your fingers are against the bottom of the nose, and press the plunger firmly.
5. 5Rescue Breathing/CPR: If trained, perform rescue breathing or CPR until help arrives.
6. 6Stay with the Person: Monitor them closely. If they do not wake up in 2-3 minutes, give a second dose in the other nostril.

Naloxone is used as-needed for emergencies; therefore, it does not have a regular dosing schedule. It is not possible to 'miss' a dose in the traditional sense, but it is vital to ensure that your Naloxone kit is not expired and is always accessible.

There is no evidence of Naloxone toxicity even at very high doses in individuals who do not have opioids in their system. However, in opioid-dependent individuals, an 'overdose' of Naloxone refers to the administration of more than is necessary to restore breathing, which can cause severe, acute opioid withdrawal syndrome. Symptoms include intense body aches, diarrhea, tachycardia (fast heart rate), and extreme agitation. Treatment is supportive, focusing on managing the withdrawal symptoms and maintaining the airway.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or administration technique without medical guidance. Always check the expiration date on your Naloxone device.

In individuals who are not physically dependent on opioids, Naloxone typically produces no side effects. However, in those with opioid physical dependence, Naloxone causes Precipitated Opioid Withdrawal Syndrome. This is not a direct side effect of the drug itself, but a result of the sudden removal of opioids from the brain's receptors. Common symptoms include:

• Nausea and Vomiting: Often sudden and forceful immediately after the drug takes effect.
• Sweating and Chills: Profuse diaphoresis (sweating) followed by shivering.
• Tachycardia: A rapid or pounding heartbeat as the body reacts to the sudden loss of opioid-induced sedation.
• Increased Blood Pressure: A transient rise in systemic blood pressure.
• Tremors and Shaking: Involuntary muscle movements.
• Agitation and Irritability: Patients often wake up feeling confused, anxious, or aggressive due to the sudden onset of pain and withdrawal.

• Dizziness and Headache: Some patients report a throbbing headache or lightheadedness upon regaining consciousness.
• Abdominal Cramping: Severe GI distress as the opioid receptors in the gut are blocked.
• Rhinorrhea: A runny nose or sneezing, particularly common with the intranasal formulation.
• Paresthesia: Tingling or 'pins and needles' sensations in the extremities.

• Seizures: While rare, seizures have been reported, usually in the context of polydrug overdoses involving stimulants or in patients with pre-existing seizure disorders.
• Arrhythmias: Irregular heart rhythms, including ventricular tachycardia or fibrillation, have occurred, primarily in patients with pre-existing cardiovascular disease.
• Pulmonary Edema: A rare but life-threatening condition where fluid builds up in the lungs. This is thought to be a result of a massive surge in the 'fight or flight' nervous system (catecholamine surge) following rapid reversal.

> Warning: Stop taking Naloxone (if using for non-emergency titration) and call your doctor immediately if you experience any of these. In an emergency, these symptoms require advanced life support.

1. 1Chest Pain or Shortness of Breath: This could indicate cardiac stress or the development of pulmonary edema.
2. 2Severe Hallucinations or Confusion: While some agitation is expected, prolonged psychosis or profound confusion requires medical evaluation.
3. 3Signs of Anaphylaxis: Including hives, swelling of the face, lips, or throat, and difficulty swallowing. This indicates a rare allergy to Naloxone or its components.
4. 4Extreme Hypertension: A sudden, dangerous spike in blood pressure that can lead to stroke or organ damage.

Naloxone is intended for short-term, emergency use. There are no known long-term side effects associated with the occasional use of Naloxone for overdose reversal. It does not cause organ damage or cumulative toxicity. However, repeated precipitated withdrawal (if a person overdoses multiple times) can place significant stress on the cardiovascular system.

No FDA black box warnings currently exist for Naloxone.

However, the FDA does require prominent warnings regarding the risk of precipitated withdrawal and the risk of re-narcotization. The most critical warning is that Naloxone is not a substitute for emergency medical care. Because Naloxone's duration of action (30-90 minutes) is shorter than that of most opioids, the person may stop breathing again once the Naloxone wears off. This is why calling 911 is mandatory even if the person seems 'fine' after receiving the medication.

Report any unusual symptoms or adverse reactions to your healthcare provider or through the FDA MedWatch program.

Naloxone is a high-alert medication because it is used in life-or-death situations. The most important safety point is that Naloxone only works on opioids. It will not reverse the effects of an overdose caused by cocaine, methamphetamines, alcohol, or benzodiazepines (like Xanax or Valium). If a person has taken a mixture of drugs, Naloxone will only remove the opioid component of the overdose.

As of 2026, there are no FDA black box warnings for Naloxone Hydrochloride. It is considered exceptionally safe, even when administered to someone who is not actually overdosing on opioids.

• Recurrence of Respiratory Depression: This is the 're-narcotization' risk. Patients must be monitored for at least 2 to 4 hours after the last dose of Naloxone. If the opioid they took was a long-acting variety (like methadone) or a high-potency synthetic (like fentanyl), they may require a continuous IV infusion of Naloxone in a hospital.
• Cardiovascular Stress: The sudden reversal of opioid effects causes a massive release of adrenaline. In patients with pre-existing heart conditions, this can trigger heart attacks, dangerous arrhythmias, or pulmonary edema. Healthcare providers should use caution when administering Naloxone to patients with known cardiovascular disease.
• Precipitated Withdrawal: In patients who are physically dependent on opioids, Naloxone will cause immediate, severe withdrawal. While this is not usually life-threatening for adults, it is extremely distressing and can lead to the patient becoming combative or seeking more opioids immediately to stop the pain, which could lead to a second overdose.
• Risk of Aspiration: Because Naloxone often causes vomiting, and the patient may still be semi-conscious, there is a high risk of the patient inhaling their vomit into their lungs (aspiration). Always turn the person onto their side (the 'recovery position') after administering Naloxone.

In a clinical setting, the following monitoring is required after Naloxone administration:

• Continuous Pulse Oximetry: To monitor oxygen saturation levels in the blood.
• Respiratory Rate: Close observation of the depth and frequency of breaths.
• Heart Rate and Blood Pressure: To detect cardiovascular stress or arrhythmias.
• End-Tidal CO2 (Capnography): The most sensitive way to monitor for recurring respiratory depression.

Patients who have received Naloxone for an overdose should not drive or operate heavy machinery for at least 24 hours. The underlying overdose, the effects of the Naloxone, and the subsequent withdrawal symptoms all significantly impair cognitive and motor function.

Alcohol is a CNS depressant that can worsen an opioid overdose. Naloxone does not reverse the effects of alcohol. If alcohol is present in the patient's system, they may remain sedated or uncoordinated even after the Naloxone has successfully restored their breathing.

There is no 'tapering' required for Naloxone, as it is not a maintenance medication. There is no risk of addiction or withdrawal from the Naloxone itself.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before you are in a position where you might need Naloxone.

There are no drugs that are strictly contraindicated with Naloxone in an emergency setting. Because Naloxone is used to save a life, it is administered regardless of other medications the patient may be taking. However, its interaction with Opioid Agonists is the definition of its use: it will completely block and negate the effects of any opioid painkillers, including those used for chronic pain or anesthesia.

• Buprenorphine and Pentazocine: These are partial opioid agonists/antagonists. Because they bind very tightly to the opioid receptors, they are more difficult to displace than heroin or morphine. Reversing an overdose of buprenorphine may require significantly higher doses of Naloxone and longer periods of observation.
• Clonidine: Some case reports suggest that Naloxone might interfere with the blood-pressure-lowering effects of clonidine, though this is rarely clinically significant in an emergency overdose scenario.
• Cardiotoxic Drugs: Medications that prolong the QT interval or increase heart rate may increase the risk of cardiac side effects when Naloxone triggers an adrenaline surge.

• Methylnaltrexone/Naloxegol: These are peripheral opioid antagonists used for opioid-induced constipation. Taking Naloxone while on these medications will not cause a drug-drug interaction, but it will cause systemic withdrawal, whereas the others only work in the gut.

There are no known food interactions with Naloxone. Because it is administered via injection or nasal spray, the presence of food in the stomach does not affect its absorption or efficacy.

• St. John's Wort: While St. John's Wort affects many drugs via the CYP3A4 enzyme, Naloxone is primarily metabolized via glucuronidation, so there is no significant interaction.
• Kava/Valerian/Sleep Supplements: These supplements have sedative properties. Naloxone will not reverse the sedation caused by these herbs, which may lead to a 'partial' recovery where the patient breathes but remains unconscious.

Naloxone is not known to interfere with common laboratory tests, including blood chemistry, hematology, or standard urine drug screens (though the urine screen will obviously show the opioids that caused the overdose).

For each major interaction, the mechanism is usually pharmacodynamic (acting on the same receptor or physiological system) rather than pharmacokinetic (changing the levels of the drug in the blood). The clinical consequence is usually a reduction in the efficacy of pain medications or an increase in the intensity of withdrawal symptoms. Management strategy always prioritizes the restoration of breathing over the management of secondary interactions.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are on a supervised pain management plan.

There is only one absolute contraindication for the use of Naloxone:

• Known Hypersensitivity: Naloxone should not be administered to individuals with a known, documented allergy to Naloxone Hydrochloride or any of the inactive ingredients (such as benzalkonium chloride in nasal sprays). An allergic reaction could manifest as anaphylaxis, which would further complicate the respiratory distress of an overdose. However, in a life-threatening emergency where the cause of the allergy is unknown, the benefits of Naloxone usually outweigh the risks, and it is administered followed by immediate treatment for the allergic reaction.

Relative contraindications require a healthcare provider to weigh the risks against the life-saving benefits:

• Pre-existing Cardiac Disease: Patients with a history of heart failure, recent heart attack, or significant arrhythmias are at higher risk for cardiac complications during the adrenaline surge that follows Naloxone administration.
• Pregnancy: While not a contraindication, Naloxone can cause fetal distress by inducing withdrawal in the fetus. It should be used only if clearly needed to save the mother's life.
• Opioid Physical Dependence: In these patients, Naloxone will cause acute withdrawal. This is not a reason to withhold the drug in an overdose, but it is a reason to be prepared for the physical and behavioral consequences.

There is a potential for cross-sensitivity between Naloxone and other morphinan-type antagonists, such as Naltrexone or Nalmefene. If a patient has had a severe reaction to Naltrexone (used for alcohol or opioid dependence), healthcare providers should be prepared for a similar reaction to Naloxone.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Naloxone for you to keep on hand. In an emergency, bystanders should follow the 'save a life first' principle.

Naloxone is classified as FDA Pregnancy Category B (under the old system). This means that animal studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Risks: Naloxone crosses the placenta. In an opioid-dependent pregnant woman, Naloxone may precipitate withdrawal in both the mother and the fetus. Fetal withdrawal can lead to fetal distress, premature labor, or even fetal demise.
• Clinical Decision: Despite these risks, the primary danger to a fetus during an overdose is the mother's respiratory failure and the resulting lack of oxygen (hypoxia). Therefore, Naloxone should be administered to a pregnant woman in an overdose situation, as saving the mother's life is the best way to save the fetus.

It is not known whether Naloxone is excreted in human milk. However, because Naloxone has extremely low oral bioavailability, even if a nursing infant were to ingest milk containing Naloxone, very little would be absorbed into their bloodstream. The risk to a nursing infant is considered minimal, but mothers should consult their healthcare provider if they require Naloxone while breastfeeding.

Naloxone is safe for use in children of all ages. For neonates, it is used to reverse respiratory depression caused by opioids given to the mother during labor. It is important to monitor pediatric patients very closely, as they may be more sensitive to the effects of withdrawal and may have smaller oxygen reserves than adults. Naloxone is not approved for any use in children other than the reversal of opioid effects.

In elderly patients, the primary concern is the cardiovascular system. Older adults are more likely to have underlying hypertension, coronary artery disease, or arrhythmias. The sudden surge in catecholamines (adrenaline) following Naloxone administration can trigger a cardiac event. Healthcare providers should monitor elderly patients with continuous EKG if possible during the reversal process.

While Naloxone is primarily metabolized by the liver, its metabolites are cleared by the kidneys. In patients with severe renal impairment or GFR < 30 mL/min, these metabolites may accumulate. While the metabolites are not active, they could potentially cause confusion or other side effects. No specific dose adjustment is needed for emergency use.

In patients with significant liver disease (Child-Pugh Class B or C), the metabolism of Naloxone is slowed. This may result in higher peak concentrations and a longer half-life. This does not change the need for the drug in an emergency, but it may mean the patient stays in a state of precipitated withdrawal for a longer period.

> Important: Special populations require individualized medical assessment. If you fall into one of these categories, discuss your risk profile with your doctor.

Naloxone is a pure opioid antagonist. At the molecular level, it acts as a competitive inhibitor at the Mu, Kappa, and Delta opioid receptors in the Central Nervous System (CNS). It has the highest affinity for the Mu-opioid receptor, which is the primary receptor responsible for the analgesic (pain-killing) and respiratory-depressant effects of opioids.

Naloxone's structure is very similar to that of oxymorphone, but it has an allyl group substituted on the nitrogen atom. This small chemical change allows it to bind to the receptor pocket with high precision but prevents it from 'tripping' the molecular switch that would activate the G-protein signaling pathway. By occupying the receptor, it prevents opioid molecules from binding, effectively neutralizing their effect.

Naloxone has no agonist activity, meaning it produces no effect in the absence of opioids. It does not cause respiratory depression, miosis (pinpoint pupils), or psychic effects. In the presence of opioids, the dose-response relationship is very steep; once a threshold dose is reached, reversal of sedation and respiratory depression is rapid (usually within 2 minutes IV and 5 minutes IM/IN). The duration of effect is dose-dependent but typically lasts 30 to 90 minutes.

| Parameter | Value |

|---|---|

| Bioavailability | ~2% (Oral), ~47-54% (Intranasal) |

| Protein Binding | 32% - 45% (primarily Albumin) |

| Half-life | 30 - 90 minutes (Adults); up to 3 hours (Neonates) |

| Tmax | 20 - 30 minutes (Intranasal) |

| Metabolism | Hepatic (Glucuronidation via UGT2B7) |

| Excretion | Renal (70% as metabolites within 72 hours) |

• Molecular Formula: C19H21NO4
• Molecular Weight: 327.37 g/mol (as base); 363.84 g/mol (as HCl salt)
• Solubility: Soluble in water, dilute acids, and strong alkali; slightly soluble in alcohol.
• Structure: A synthetic congener of oxymorphone, characterized by a 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one structure.

Naloxone is the prototypical member of the Opioid Antagonist class. Related medications include Naltrexone (used for long-term maintenance/alcoholism) and Nalmefene (a longer-acting antagonist). Unlike Buprenorphine, which is a partial agonist, Naloxone provides zero activation of the receptors.